Literature DB >> 28546645

Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias.

Thomas M Jeitner1, Eva Kristoferson1, Juan A Azcona1, John T Pinto1, Clint Stalnecker2, Jon W Erickson2, Hank F Kung3, Jianyong Li4, Karl Ploessl3, Arthur J L Cooper1.   

Abstract

Two 4-fluoro-L-glutamine diastereoisomers [(2S,4R)-4-FGln, (2S,4S)-4-FGln] were previously developed for positron emission tomography. Label uptake into two tumor cell types was greater with [18F](2S,4R)-4-FGln than with [18F](2S,4S)-4-FGln. In the present work we investigated the enzymology of two diastereoisomers of 4-FGln, two diastereoisomers of 4-fluoroglutamate (4-FGlu) (potential metabolites of the 4-FGln diastereoisomers) and another fluoro-derivative of L-glutamine [(2S,4S)-4-(3-fluoropropyl)glutamine (FP-Gln)]. The two 4-FGlu diastereoisomers were found to be moderate-to-good substrates relative to L-glutamate of glutamate dehydrogenase, aspartate aminotransferase and alanine aminotransferase. Additionally, alanine aminotransferase was shown to catalyze an unusual γ-elimination reaction with both 4-FGlu diastereoisomers. Both 4-FGlu diastereoisomers were shown to be poor substrates, but strong inhibitors of glutamine synthetase. Both 4-FGln diastereoisomers were shown to be poor substrates compared to L-glutamine of glutamine transaminase L and α-aminoadipate aminotransferase. However, (2S,4R)-4-FGln was found to be a poor substrate of glutamine transaminase K, whereas (2S,4S)-4-FGln was shown to be an excellent substrate. By contrast, FP-Gln was found to be a poor substrate of all enzymes examined. Evidently, substitution of H in position 4 by F in L-glutamine/L-glutamate has moderate-to-profound effects on enzyme-catalyzed reactions. The present results: 1) show that 4-FGln and 4-FGlu diastereoisomers may be useful for studying active site topology of glutamate- and glutamine-utilizing enzymes; 2) provide a framework for understanding possible metabolic transformations in tumors of 18F-labeled (2S,4R)-4-FGln, (2S,4S)-4-FGln, (2S,4R)-4-FGlu or (2S,4S)-4-FGlu; and 3) show that [18F]FP-Gln is likely to be much less metabolically active in vivo than are the [18F]4-FGln diastereoisomers.

Entities:  

Keywords:  Fluoroglutamate; Fluoroglutamine; Glutamate-utilizing enzymes; Glutamine-utilizing enzymes

Year:  2016        PMID: 28546645      PMCID: PMC5440087          DOI: 10.1016/j.jfluchem.2016.10.008

Source DB:  PubMed          Journal:  J Fluor Chem        ISSN: 0022-1139            Impact factor:   2.050


  49 in total

1.  Spectrophotometric measurement of alpha-keto acid semicarbazones.

Authors:  J A OLSON
Journal:  Arch Biochem Biophys       Date:  1959-11       Impact factor: 4.013

2.  Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.

Authors:  Arthur J L Cooper; Boris F Krasnikov; John T Pinto; Hank F Kung; Jianyong Li; Karl Ploessl
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2012-05-19       Impact factor: 2.231

3.  A sensitive fluorometric assay for amino acid oxidases.

Authors:  L A Lichtenberg; D Wellner
Journal:  Anal Biochem       Date:  1968-11       Impact factor: 3.365

4.  PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Authors:  Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung
Journal:  J Nucl Med       Date:  2011-11-15       Impact factor: 10.057

5.  Stimulation of the hydrolytic activity and decrease of the transpeptidase activity of gamma-glutamyl transpeptidase by maleate; identity of a rat kidney maleate-stimulated glutaminase and gamma-glutamyl transpeptidase.

Authors:  S S Tate; A Meister
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

Review 6.  Glutamine in neoplastic cells: focus on the expression and roles of glutaminases.

Authors:  Monika Szeliga; Marta Obara-Michlewska
Journal:  Neurochem Int       Date:  2009-02-07       Impact factor: 3.921

Review 7.  Glutaminase regulation in cancer cells: a druggable chain of events.

Authors:  William P Katt; Richard A Cerione
Journal:  Drug Discov Today       Date:  2013-10-16       Impact factor: 7.851

8.  Biochemical and structural properties of mouse kynurenine aminotransferase III.

Authors:  Qian Han; Howard Robinson; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Mol Cell Biol       Date:  2008-11-24       Impact factor: 4.272

9.  Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.

Authors:  John T Pinto; Tetyana Khomenko; Sandor Szabo; Gordon D McLaren; Travis T Denton; Boris F Krasnikov; Thomas M Jeitner; Arthur J L Cooper
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-05-28       Impact factor: 3.205

10.  Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Authors:  Saverio Tardito; Anaïs Oudin; Shafiq U Ahmed; Fred Fack; Olivier Keunen; Liang Zheng; Hrvoje Miletic; Per Øystein Sakariassen; Adam Weinstock; Allon Wagner; Susan L Lindsay; Andreas K Hock; Susan C Barnett; Eytan Ruppin; Svein Harald Mørkve; Morten Lund-Johansen; Anthony J Chalmers; Rolf Bjerkvig; Simone P Niclou; Eyal Gottlieb
Journal:  Nat Cell Biol       Date:  2015-11-23       Impact factor: 28.824

View more
  2 in total

1.  Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization.

Authors:  Adam J Rosenberg; Michael L Nickels; Michael L Schulte; H Charles Manning
Journal:  Nucl Med Biol       Date:  2018-10-15       Impact factor: 2.408

2.  The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites.

Authors:  Vivek A Hariharan; Travis T Denton; Sarah Paraszcszak; Kyle McEvoy; Thomas M Jeitner; Boris F Krasnikov; Arthur J L Cooper
Journal:  Biology (Basel)       Date:  2017-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.